GABARAPL1 and Wilson disease: We prove that GDL may inhibit the malignant overexpression of Atg12 and Gabarapl1 through the PI3K/Akt/FoxO1 and Sirt1/FoxO1 pathways, thereby improving the neural function and improving nerve injury in the high‐copper‐induced WD rat model.